Dermatology 2026

Vitiligo is a chronic dyschromic disorder characterized by the progressive loss of epidermal melanocytes and is influenced by a complex interplay of genetic and epigenetic factors, oxidative stress, and immune-mediated mechanisms involving cytotoxic T cells and interferon gamma. Clinical diagnosis primarily distinguishes between segmental vitiligo, which commonly occurs in children and follows a localized distribution, and nonsegmental vitiligo, which is typically bilateral and symmetrical.

Modern therapeutic approaches are increasingly personalized according to disease activity, extent, patient characteristics, and treatment goals, including stabilization, repigmentation, and, in exceptional cases, depigmentation. Among repigmentation strategies, narrowband ultraviolet B (NB-UVB) phototherapy remains an established and effective treatment option, with clinical studies demonstrating progressive improvement following sustained treatment. Recent advances have introduced targeted therapies, particularly Janus kinase (JAK) inhibitors. Ruxolitinib cream represents an important therapeutic development and is the first licensed topical treatment for facial nonsegmental vitiligo in several regulatory settings. Despite its efficacy, cost and accessibility remain important considerations. Other targeted therapies, including baricitinib, upadacitinib, and povorcitinib, are currently being investigated, alongside emerging therapeutic approaches and novel treatment protocols.

An increasingly important aspect of vitiligo management is the assessment of its psychological and social impact. International consensus increasingly emphasizes patient-reported outcomes and quality of life alongside clinical disease severity. Contemporary management therefore extends beyond restoration of pigmentation to encompass emotional well-being, social functioning, and patient-centered care.

These developments demonstrate the transition of vitiligo management toward personalized and precision-based dermatology, with the ultimate goal of improving both skin repigmentation and overall quality of life.

Dr. Margarita Colotti is a dermatology specialist based in Córdoba, Argentina. She currently practices as a dermatologist at Instituto Strusberg, where she also contributes as a sub-investigator in Clinical Trials. Her professional work combines clinical dermatology with research, reflecting her interest in advancing evidence-based approaches to the diagnosis and treatment of skin conditions.

Dr. Colotti completed her medical education at the National University of Córdoba, where she trained as a specialist in General Medicine and Dermatology. Her experience in clinical practice and clinical research enables her to contribute to the development and evaluation of innovative dermatological treatments.